News Sentiment

AGEN sentiment intelligence

Agenus Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 58 Balanced news tone 58 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 3.35 Week of 10 Jul 2026
Weighted tone 58/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

84/100 classification confidence.

Company focus 50

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

-4.0% over one week, +1.5% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

Agenus (AGEN) Could Be 83% Undervalued On Phase 1b Data And $340 Million Raise

Market Reaction

Price moving ahead of tone

69/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 84/100 classification
One-week reaction -4.0% Price reacting lower
Trend fit Trend inactive 1.5% over four weeks
Fair value -59.0% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 20
Neutral 35
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 50
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 10
Stock Titan 7
simplywall.st 4
Oncodaily 4
TradingView 4
Investing.com 4
Benzinga 3
Business Wire 3

Event Lens

What the news is about

Classified themes
Market update 38
Earnings 11
Balance sheet 4
Deals and strategy 3
Analyst action 1
Regulatory and legal 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 58
Stock Titan Direct company coverage

Agenus Inc. (NASDAQ: AGEN) director takes 4,852-share stock salary grant

Agenus Inc. director Garo H. Armen received a grant of 4,852 shares of common stock on July 10, 2026, as compensation for his salary in lieu of cash. The shares, valued at $3.35 each, are fully vested and were issued under the company's 2019 Equity Incentive plan. Following this

Tone
Neutral 50/100
Event
Balance sheet
Published
14 Jul 2026 19:39
Source
Stock Titan
Oncodaily Direct company coverage

From “Most Promising” to Phase 3: Up to $340M to Advance BOT/BAL in MSS Colon Cancer

Agenus has secured up to $340 million in a private placement to fund a registrational Phase 3 trial (ROBBIN) of its combination therapy BOT/BAL for microsatellite-stable (MSS) colon cancer. This financing follows two years of promising clinical data, including durable survival ra

Tone
Positive 72/100
Event
Market update
Published
14 Jul 2026 17:39
Source
Oncodaily
StocksToTrade Direct company coverage

AGEN Stock Pulls Back After Huge Spike As Traders Dig Into Financials

Agenus Inc. (AGEN) stock experienced a significant pullback after a recent price surge, prompting traders to scrutinize its financials. While the company shows strong revenue growth, its balance sheet reveals weak liquidity with negative equity and working capital. The article hi

Tone
Negative 35/100
Event
Earnings
Published
14 Jul 2026 17:03
Source
StocksToTrade
TradingView Direct company coverage

AGEN Stock Jumps on Securing $340M Financing to Fund Strategic Pivot

Agenus (AGEN) shares surged nearly 83% after securing an oversubscribed private placement of up to $340 million. This financing is intended to fund a strategic pivot towards a registrational Phase III study for colon cancer, extending the company’s cash runway through 2031 if war

Tone
Neutral 50/100
Event
Balance sheet
Published
14 Jul 2026 15:39
Source
TradingView
CancerNetwork Direct company coverage

Agenus Discontinues Phase 3 BATTMAN Trial in Metastatic MSS Colorectal Cancer

Agenus Inc. has halted financial support for its phase 3 BATTMAN trial evaluating botensilimab plus balstilimab (BOT+BAL) in late-line metastatic microsatellite-stable (MSS) colorectal cancer. This decision is driven by a strategic shift to prioritize the planned phase 3 ROBBIN t

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 15:39
Source
CancerNetwork
Pluang Direct company coverage

Agenus raises up to $340M to fund Phase 3 trial for colon cancer immunotherapy.

Agenus Inc. has secured up to $340 million through an oversubscribed private placement to finance a Phase 3 trial for its immunotherapy combination BOT+BAL, targeting microsatellite-stable colon cancer. The ROBBIN trial aims to enroll 850 patients globally, with initial dosing in

Tone
Positive 90/100
Event
Market update
Published
14 Jul 2026 06:13
Source
Pluang
Market source Direct company coverage

Agenus shares surge as company secures up to $340M to advance colon cancer trial

Agenus shares surged by approximately 100% after the company secured up to $340 million through an oversubscribed private placement to fund its ROBBIN Phase 3 trial. This trial will evaluate the BOT+BAL immunotherapy combination for microsatellite-stable (MSS) colon cancer. The f

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 01:39
Source
Market source
Quartr Direct company coverage

Agenus (AGEN) Investor update Summary

Agenus is focusing its efforts on neoadjuvant BOT/BAL for high-risk Stage II/III MSS colon cancer, supported by strong clinical data and a planned Phase 3 trial. The company secured up to $340 million in financing to fund the ROBBIN Phase 3 trial and operations through 2031, targ

Tone
Positive 81/100
Event
Market update
Published
14 Jul 2026 01:10
Source
Quartr
Oncodaily Direct company coverage

Agenus Secures Up to $340M to Advance ROBBIN and Prioritize Neoadjuvant BOT/BAL in MSS Colon Cancer

Agenus Inc. has secured up to $340 million through an oversubscribed private placement to advance its Phase 3 ROBBIN trial, evaluating neoadjuvant botensilimab plus balstilimab (BOT+BAL) in microsatellite-stable (MSS) colon cancer. This financing allows Agenus to prioritize the R

Tone
Positive 71/100
Event
Market update
Published
13 Jul 2026 20:10
Source
Oncodaily
Investing.com Direct company coverage

H.C. Wainwright raises Agenus stock price target to $30 on strategy shift

H.C. Wainwright has increased its price target for Agenus Inc. from $23 to $30, maintaining a Buy rating, following the biotech company's strategic shift in developing bot/bal for neoadjuvant MSS-CRC. The firm updated its financial model assuming a 2030 launch and anticipates $2.

Tone
Positive 72/100
Event
Analyst action
Published
13 Jul 2026 17:10
Source
Investing.com
citybiz Direct company coverage

Agenus Secures Up to $340 Million to Advance Phase 3 Colon Cancer Trial

Agenus Inc. has secured up to $340 million through an oversubscribed private placement to fund the late-stage development of its immunotherapy combination, botensilimab and balstilimab (BOT+BAL), for high-risk Stage II and Stage III microsatellite-stable (MSS) colon cancer. This

Tone
Positive 71/100
Event
Market update
Published
13 Jul 2026 12:31
Source
citybiz
Investing.com Direct company coverage

Agenus stock jumps on $85 million private placement financing

Agenus Inc. (NASDAQ:AGEN) shares rose 13% in premarket trading after announcing an $85 million private placement, with a potential total of $340 million upon full warrant exercise. The funds will support its ROBBIN Phase 3 trial, extending its cash runway through 2031, while the

Tone
Positive 81/100
Event
Balance sheet
Published
13 Jul 2026 10:41
Source
Investing.com
TradingView Direct company coverage

Agenus Raises $85 Million in Private Placement, Warrants Could Add $255 Million More

Agenus announced a private placement that is expected to raise approximately $85 million in gross proceeds. Additionally, Series A and Series B warrants could generate up to an extra $255 million if fully exercised, with the closing anticipated on July 15, 2026. The funds will be

Tone
Positive 72/100
Event
Market update
Published
13 Jul 2026 10:41
Source
TradingView
Stock Titan Direct company coverage

[8-K] AGENUS INC Reports Material Event

Agenus Inc. has filed an 8-K report detailing a securities purchase agreement for a private placement expected to close on July 15, 2026. This financing, totaling up to $340 million, will fund the strategic prioritization of botensilimab and balstilimab (BOT+BAL) for neoadjuvant

Tone
Positive 71/100
Event
Market update
Published
13 Jul 2026 10:41
Source
Stock Titan
Business Wire Direct company coverage

Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer

Agenus Inc. has announced an oversubscribed private placement of up to $340 million to fund its registrational Phase 3 ROBBIN trial for neoadjuvant botensilimab and balstilimab (BOT+BAL) in microsatellite-stable (MSS) colon cancer. This financing includes $85 million upfront and

Tone
Positive 70/100
Event
Market update
Published
13 Jul 2026 09:41
Source
Business Wire